Coronavirus / COVID

Investigators observed a second set of virus in a previously infected 33-year-old man, nearly 5 months after his first positive COVID-19 case.

An infectious disease chief medical officer discusses the cracks in US healthcare exposed by the pandemic.

Obesity was a risk factor for intubation and death from COVID-19 for adults under the age of 65.

The newest authorization comes following a week of clinical, legislative, and public health debate surrounding the realistic benefit of the survivor-extracted therapy.

Martin Kulldorff, PhD, explains the standard Sweden uses to collect data on the country's seemingly high COVID-19 mortality.

The IDSA recommends against its use in the hospital setting.

Martin Kulldorff, PhD, explains how an age-based focus for COVID-19 mitigation might better protect both older people and younger people with comorbidities.

School administrators, nurses and teachers are trying to develop plans to bring students back for critical in-school learning while keeping staff and immune-suppressed students safe.

The vaccine candidate, BNT162b2, was well-tolerated and phase 3 enrollment is more than one-third complete.

Rodney E. Rohde, a clinical laboratory specialist at Texas State University, goes into the competing priorities of college and K-12 school reopening.

Scientists are willing to speak out and have collegial debates – but medical institutions and media have to catch up: fringe voices are often the only ones platformed to discuss important scientific nuances or debates.

In unexposed blood samples, investigators discovered memory helper T cells that recognize cold coronaviruses also recognized SARS-CoV-2, and may help people fight off the virus.

Postmarketing vaccine experience with vaccines suggests the candidates approved by the FDA for COVID-19 will be safe and effective

A University of Maryland Professor of Pathology explains that SARS-CoV-2 has unique ways of evading detection.

Pediatricians agree schools are critical for child development and mental health. But their safety from the pandemic cannot be comprised for it.

The US FDA was said to be considering an emergency authorization for COVID-19 plasma just last week. For now, the authorization is on hold.

Join us tomorrow for an informative discussion on CDC guidance and insights from medical experts on navigating a way back to in-school learning.

Symptomatic case fatality ratio and infection fatality ratio provide a more accurate picture of pandemic, they say.

Citing the rise of the anti-vaccine movement, Peter Hotez, MD, PhD, explains the role scientists can play in building trust and literacy by engaging the public.

Rodney E. Rohde, PhD, a clinical laboratory scientist, helps break down how carefully EUA releases need to be read in order for the public and for scientists from other fields to parse them for useful information.

From immunity building to plasma research, a look at some lesser efficient practices adopted or proposed during the pandemic.

The ideal time to act on COVID-19 was in January, says public health expert Raj Bhopal.

The US CDC has been engaged in a back and forth with media for several days after reductionist reporting on immunity related to COVID-19 suggested categorical proof of antibody based immunity to reinfection.

In a small study, preliminary analysis shows patients given this treatment early in hospitalization showed improvement and reduced mortality rates.

Use of an IL-6 inhibitor has the potential to prevent the cytokine storm caused by severe COVID-19 infection.

July ended with nearly 100,000 new cases among children in the US. What does that mean for public and school reopenings?

SalivaDirect is unique in that it does not require a particular type of swab or collection device; any sterile container is suitable for saliva collection with the test.

Armand Balboni, MD, PhD, discusses progress toward FDA authorization and/or approval of favipiravir for COVID-19 as a prophylactic measure.

The American College of Physicians says it no longer plans to update its rapid, living practice points because it doesn’t believe new evidence will support the use of the antiviral medications in the fight against COVID-19.